Literature DB >> 31915854

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.

Morten Orebo Holmström1, Sabrina Cordua2, Vibe Skov2, Lasse Kjær2, Niels Pallisgaard3, Christina Ellervik4,5,6, Hans Carl Hasselbalch2, Mads Hald Andersen7,8.   

Abstract

There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (CALR) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR-mutation can recognize and kill autologous CALR-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR-mutant cells in the editing stage for several years. Thus, we suggest that CALR-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR-mutant MPN displays all three stages described in the theory of cancer immuno-editing.

Entities:  

Keywords:  CALR; CITIM 2019; Immuno-editing; Myeloproliferative neoplasms; Neo-antigen; T cell memory

Mesh:

Substances:

Year:  2020        PMID: 31915854     DOI: 10.1007/s00262-019-02473-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression.

Authors:  Ana Micaela Carnaz Simões; Morten Orebo Holmström; Pia Aehnlich; Anne Rahbech; Aneta Radziwon-Balicka; Carlos Zamora; Tobias Wirenfeldt Klausen; Vibe Skov; Lasse Kjær; Christina Ellervik; Daniel El Fassi; Silvia Vidal; Hans Carl Hasselbalch; Mads Hald Andersen; Per Thor Straten
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

Review 2.  The Role of the RNA-Binding Protein Family MEX-3 in Tumorigenesis.

Authors:  Simon Jasinski-Bergner; André Steven; Barbara Seliger
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

3.  Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.

Authors:  Jacob Handlos Grauslund; Morten Orebo Holmström; Nicolai Grønne Jørgensen; Uffe Klausen; Stine Emilie Weis-Banke; Daniel El Fassi; Claudia Schöllkopf; Mette Borg Clausen; Lise Mette Rahbek Gjerdrum; Marie Fredslund Breinholt; Julie Westerlin Kjeldsen; Morten Hansen; Steffen Koschmieder; Nicolas Chatain; Guy Wayne Novotny; Jesper Petersen; Lasse Kjær; Vibe Skov; Özcan Met; Inge Marie Svane; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

Review 4.  Targeting macrophages in hematological malignancies: recent advances and future directions.

Authors:  Wei Li; Fang Wang; Rongqun Guo; Zhilei Bian; Yongping Song
Journal:  J Hematol Oncol       Date:  2022-08-17       Impact factor: 23.168

5.  A Comprehensive Analysis of HAVCR1 as a Prognostic and Diagnostic Marker for Pan-Cancer.

Authors:  Sheng Liu; Wenting Tang; Jing Cao; Mei Shang; Hengchang Sun; Jiao Gong; Bo Hu
Journal:  Front Genet       Date:  2022-06-08       Impact factor: 4.772

Review 6.  The mechanisms of action of Plasmodium infection against cancer.

Authors:  Xiaoping Chen; Li Qin; Wen Hu; Dickson Adah
Journal:  Cell Commun Signal       Date:  2021-07-09       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.